

NEWSLETTER January – February 2020

CEO's greetings

Safety is always the primary endpoint in a first-in-human clinical study. Nevertheless, I admit that I also hoped to see some signal of efficacy after 12 months of treatment in our first CDNF study. Even though this study only recruited patients with advanced Parkinson's disease: widely admitted as a suboptimal target group for the neuroprotective and neurorestorative CDNF therapy.

We were however very positively surprised to see such signals already after the first 6 months! And importantly, signals in DAT-PET imaging, which many experts considered beforehand as the most compelling exploratory endpoint in our study.

Let's keep in mind that the clinical study continues. We are really looking forward to the 12-month results in Q3, hoping that the encouraging signals will be at least sustained. In any case this is a first-in-human study and its primary endpoint is safety. Needless to say, we were very pleased that CDNF is so far considered safe and well tolerated.

CLINICAL STUDIES

- **Breast Cancer Associated Lymphedema:** Phase 2 study AdeLE is fully recruited. Results are expected in Q1/21 after a 12-month blinded follow-up. See [Lymfactin website](#) for details.
- **Parkinson's disease:** Phase 1-2 study with CDNF is fully recruited. Based on 6-month results CDNF is safe with encouraging biological signals in some patients. 12-month results are expected in Q3/20.
- **Breast Cancer Associated Lymphedema:** Phase 1 study is in long-term follow-up. Based on 12-month follow-up, Lymfactin® is safe and well tolerated.

PLANNED ACTIVITIES

- **Annual Report for 2019**, 17 Mar 2020
- **Osakesäästäjät Helsinki**, 18 Mar 2020: Company presentation to Finnish investors in Helsinki
- **ABGSC Investor Days at Haymarket**, 19 Mar 2020 in Stockholm: Company presentation to Swedish investors
- **AD/PD conference**, 2-5 April 2020 in Vienna (Advances in Alzheimer's and Parkinson's Therapies)
- **Annual General Meeting**, 8 Apr 2020 in Helsinki
- **99th AAPS meeting**, 3 May 2020 in Chicago, IL, USA. Herantis' Lymfactin presentation at AAPS (American Association of Plastic Surgeons)
- **Sijoitusmessut**, 14 May 2020 in Tampere, Finland. Company presentation to Finnish investors.

Herantis of the month



*A usual day at the office.
Printing is not a strength of our CEO...*

Keep up-to-date on Herantis:



Highlights from team

Very obviously, the first glimpse to 6-month results in Parkinson's was a real highlight for our team. A promising signal at this stage was also a well-earned reward for years of hard work.

J.P. Morgan Healthcare Conference is an annual highlight in January, hotel-hopping around Union Square in San Francisco, meeting investors and Big Pharma. We had promised topline data from our Parkinson's study in Q1. So, in almost every conversation, we were asked: "Will it be early Q1, or late Q1?"

Topics of interest

We held a live webcast on Feb 28 to elaborate on the topline results of the first 6 months of our Phase 1-2 study in Parkinson's. The [presentation](#) is available on our website. The full webcast video will be added too.

Herantis' drug development is based on leading science. We aim at significant breakthroughs compared to available therapies. This is partially enabled by the high-quality Nordic education system, as suggested in our [recent blogging](#).

Herantis in the news

Herantis interviewed by [Inderes TV](#) (in Finnish) summarizing highlights of 2019, discussing anticipated key events in 2020, and elaborating on the recent Parkinson's results.

Herantis' top-line Parkinson's results [discussed in an article](#) by Simon Stott, Deputy Director of Research at the Cure Parkinson's Trust.

The "Financial Times of Finland", Kauppalehti, [noted](#) Herantis' promising Parkinson's results (in Finnish)